Journal
CELL METABOLISM
Volume 28, Issue 6, Pages 808-810Publisher
CELL PRESS
DOI: 10.1016/j.cmet.2018.11.012
Keywords
-
Categories
Funding
- Canadian Institutes of Health Research (CIHR) Foundation Grant [FDN-143204]
- Diabetes Canada Operating Grant [OG-2-15-4901-TL]
- Juvenile Diabetes Research Foundation (JDRF) [17-2013-312]
- Canadian Diabetes Association
- CIHR-JDRF SPOR operating grant
- Banting and Best Diabetes Centre
- University of Toronto Department of Medicine Merit Award
Ask authors/readers for more resources
Metformin is a first-line glucose-lowering agent in patients with type 2 diabetes (T2D). Recently in Nature Medicine, Sun et al. (2018) reported that short-term metformin therapy decreases gut Bacteroides fragilis, consequently increasing glycoursodexoycholic acid (GUDCA) levels in humans. As an antagonist of FXR, GUDCA may carry therapeutic potential in the treatment of T2D.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available
Share Paper
